Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Nanoemulsion Technology Facilitates Drug Delivery

By Drug Discovery Trends Editor | May 14, 2010

nanobio.jpg

click to enlarge

Mechanism of action for nanoemulsion-based vaccines. (Source: NanoBio)

NanoBio Corporation is focused on developing and commercializing products based on its NanoStat technology. The platform provides the basis for therapeutic applications including intranasal vaccines (RSV, influenza), topical dermatological treatments (onychomycosis, acne), and anti-infectives (bacterial infections related to cystic fibrosis of the lung or COPD).

Clinical candidates derived from the NanoStat platform have shown activity against bacteria, viruses, fungi, and spores. A topical dermatological product derived from the platform works with nanoemulsion droplets that rapidly penetrate through pores and hair shafts to the site of the infection and physically disrupt the outer membrane of pathogenic organisms by fusing with and killing lipid-containing organisms. Unlike currently available therapies, NanoBio’s treatments are selectively toxic to microbes while non-irritating to skin and mucous membranes.1

In December 2009, NanoBio and GlaxoSmithKline plc (GSK) signed an exclusive licensing agreement in the United States. and Canada for the over-the-counter use of NanoBio’s investigational compound, NB-001, for the treatment of cold sores. NB-001 demonstrated clear efficacy and safety in randomized, double-blind, placebo-controlled Phase 2a and Phase 2b studies involving over 800 subjects with recurrent herpes labialis. In the Phase 2b study of 482 patients, NanoBio’s targeted Phase 3 topical dose healed patients 1.3 days faster than placebo. In both the 2a and 2b trials, NB-001 was well-tolerated with no safety concerns or adverse events reported. NanoBio is currently preparing to study the efficacy and safety of 0.3% NB-001 in two Phase 3 trials. GSK plans to build on its Abreva brand platform with NB-001.

NanoBio’s nanoemulsion-based intra-nasal vaccines are capable of permeating the nasal mucosa, where it loads vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus, and spleen producing both mucosal immunity and systemic immune response. Virtually any bacterial or viral disease that results in a human immune response is a potential candidate for the development of a nanoemulsion-based mucosal vaccine. Active development programs are underway for influenza, respiratory syncytial virus, pneumococcal infection, hepatitis B, anthrax, smallpox, cancer, and other diseases.

NanoBio’s lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown promising results in a recently completed Phase 1 clinical study. The results of the Phase 1 trial, combined with research efforts aimed at identifying the most viable nanoemulsion adjuvants, will guide the future development of nanoemulsion-based vaccines. However, data suggests that NanoBio’s treatment could play a key role in addressing pandemic situations by requiring far less antigen to elicit an immune response and also by potentially protecting against unanticipated strains of the virus. The company is currently in partnership discussions with several parties regarding NB-1008.

Reference
1. Hamouda T, Myc A, Donovan B, Shih A, Reuter J, Baker J, Jr. Novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res. 2001;156(1):1-7.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE